Another Web

About Us

Pipeline

Press Releases

Location

Pipeline

Pipeline
JIN-A04

JIN-A04

Introduction of JIN-A04

Oral tyrosine kinase inhibitor targeting HER2 and EGFR exon 20 insertion mutations in NSCLC.

Key Research Findings of JIN-A04

Technology licensing agreement between Yuhan Corporation and J INTS BIO… "First step toward development of the next 'Leclaza'"
On the 30th, Yuhan Corporation (CEO Wook-je Jo) signed a technology license agreement with J INTS BIO (CEO Anna Jo) for the HER2-targeting tyrosine kinase inhibitor (TKI), ‘JIN-A04.’ The total contract value is approximately USD 318 million, including an upfront payment of USD 1.85 million and milestone payments tied to development, approval, and sales. JIN-A04 is a novel oral TKI drug candidate targeting the HER2 insertion mutation in NSCLC; currently, no approved oral drugs target this mutation. At the 2023 American Association for Cancer Research meeting, J INTS BIO presented preclinical data on JIN-A04 via poster, demonstrating potent efficacy in vitro and in vivo studies.

JIN-A04 Conference Presentation Status

Conference	Topic
2025 AACR (Poster presentation)	Preclinical
2023 WCLC (Poster presentation)	Preclinical
2023 AACR (Poster presentation)	Preclinical

AACR: American Association for Cancer Research
WCLC: World Conference on Lung Cancer

National Research and Development Project

Selection as a project in the 1st phase of the 2025 National New Drug Development Program funded by KDDF